Cost effectiveness of Interferon α2b combined with ribavirin for the treatment of chronic hepatitis C

Zobair M. Younossi, Mendel E. Singer, John G. Mchutchison, Kenneth M Shermock

Research output: Contribution to journalArticle

Abstract

Treatment of chronic hepatitis C with Interferon (IFN) α2b monotherapy results in 10% to 15% sustained virological response (SVR). Combining IFN with ribavirin increases this response. In this analysis, using the Markov model, 6 treatment strategies for chronic hepatitis C (previously untreated) were compared on the basis of incremental cost per additional quality- adjusted life years ($/QALY). Our results showed that the no treatment strategy was associated with a cost of $38,747 and 13.10 QALYs. The strategy using IFN alone for 48 weeks was associated with a cost of $35,642 and 14.05 QALYs. The strategy using IFN monotherapy followed by combination therapy for nonresponders and relapsers was associated with a cost of $34,561 and 15.53 QALYs. A similar strategy, but limiting combination to relapsers only, was associated with a cost of $34,758 and 14.40 QALYs. The strategy using IFN with ribavirin as the initial therapy for all patients was associated with a cost of $34,792 and 15.31 QALYs. Finally, the strategy using viral genotyping first and then adjusting the duration of combination therapy based on genotype was associated with a cost of $37,263 and 15.89 QALYs. The strategy using genotyping to guide duration of combination therapy was the most cost- effective approach with an incremental cost-effectiveness ratio of $7,500 per QALY. Sensitivity analyses confirmed the robustness of these results. We conclude that combination of IFN and ribavirin with duration of therapy based on the viral genotype, is a cost-effective approach in treating patients with chronic hepatitis C.

Original languageEnglish (US)
Pages (from-to)1318-1324
Number of pages7
JournalHepatology
Volume30
Issue number5
DOIs
StatePublished - 1999
Externally publishedYes

Fingerprint

Quality-Adjusted Life Years
Ribavirin
Chronic Hepatitis C
Interferons
Cost-Benefit Analysis
Costs and Cost Analysis
Therapeutics
Genotype

ASJC Scopus subject areas

  • Hepatology

Cite this

Cost effectiveness of Interferon α2b combined with ribavirin for the treatment of chronic hepatitis C. / Younossi, Zobair M.; Singer, Mendel E.; Mchutchison, John G.; Shermock, Kenneth M.

In: Hepatology, Vol. 30, No. 5, 1999, p. 1318-1324.

Research output: Contribution to journalArticle

Younossi, Zobair M. ; Singer, Mendel E. ; Mchutchison, John G. ; Shermock, Kenneth M. / Cost effectiveness of Interferon α2b combined with ribavirin for the treatment of chronic hepatitis C. In: Hepatology. 1999 ; Vol. 30, No. 5. pp. 1318-1324.
@article{6e48cca7fee5401ba301a34b11a0aa7c,
title = "Cost effectiveness of Interferon α2b combined with ribavirin for the treatment of chronic hepatitis C",
abstract = "Treatment of chronic hepatitis C with Interferon (IFN) α2b monotherapy results in 10{\%} to 15{\%} sustained virological response (SVR). Combining IFN with ribavirin increases this response. In this analysis, using the Markov model, 6 treatment strategies for chronic hepatitis C (previously untreated) were compared on the basis of incremental cost per additional quality- adjusted life years ($/QALY). Our results showed that the no treatment strategy was associated with a cost of $38,747 and 13.10 QALYs. The strategy using IFN alone for 48 weeks was associated with a cost of $35,642 and 14.05 QALYs. The strategy using IFN monotherapy followed by combination therapy for nonresponders and relapsers was associated with a cost of $34,561 and 15.53 QALYs. A similar strategy, but limiting combination to relapsers only, was associated with a cost of $34,758 and 14.40 QALYs. The strategy using IFN with ribavirin as the initial therapy for all patients was associated with a cost of $34,792 and 15.31 QALYs. Finally, the strategy using viral genotyping first and then adjusting the duration of combination therapy based on genotype was associated with a cost of $37,263 and 15.89 QALYs. The strategy using genotyping to guide duration of combination therapy was the most cost- effective approach with an incremental cost-effectiveness ratio of $7,500 per QALY. Sensitivity analyses confirmed the robustness of these results. We conclude that combination of IFN and ribavirin with duration of therapy based on the viral genotype, is a cost-effective approach in treating patients with chronic hepatitis C.",
author = "Younossi, {Zobair M.} and Singer, {Mendel E.} and Mchutchison, {John G.} and Shermock, {Kenneth M}",
year = "1999",
doi = "10.1002/hep.510300518",
language = "English (US)",
volume = "30",
pages = "1318--1324",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Cost effectiveness of Interferon α2b combined with ribavirin for the treatment of chronic hepatitis C

AU - Younossi, Zobair M.

AU - Singer, Mendel E.

AU - Mchutchison, John G.

AU - Shermock, Kenneth M

PY - 1999

Y1 - 1999

N2 - Treatment of chronic hepatitis C with Interferon (IFN) α2b monotherapy results in 10% to 15% sustained virological response (SVR). Combining IFN with ribavirin increases this response. In this analysis, using the Markov model, 6 treatment strategies for chronic hepatitis C (previously untreated) were compared on the basis of incremental cost per additional quality- adjusted life years ($/QALY). Our results showed that the no treatment strategy was associated with a cost of $38,747 and 13.10 QALYs. The strategy using IFN alone for 48 weeks was associated with a cost of $35,642 and 14.05 QALYs. The strategy using IFN monotherapy followed by combination therapy for nonresponders and relapsers was associated with a cost of $34,561 and 15.53 QALYs. A similar strategy, but limiting combination to relapsers only, was associated with a cost of $34,758 and 14.40 QALYs. The strategy using IFN with ribavirin as the initial therapy for all patients was associated with a cost of $34,792 and 15.31 QALYs. Finally, the strategy using viral genotyping first and then adjusting the duration of combination therapy based on genotype was associated with a cost of $37,263 and 15.89 QALYs. The strategy using genotyping to guide duration of combination therapy was the most cost- effective approach with an incremental cost-effectiveness ratio of $7,500 per QALY. Sensitivity analyses confirmed the robustness of these results. We conclude that combination of IFN and ribavirin with duration of therapy based on the viral genotype, is a cost-effective approach in treating patients with chronic hepatitis C.

AB - Treatment of chronic hepatitis C with Interferon (IFN) α2b monotherapy results in 10% to 15% sustained virological response (SVR). Combining IFN with ribavirin increases this response. In this analysis, using the Markov model, 6 treatment strategies for chronic hepatitis C (previously untreated) were compared on the basis of incremental cost per additional quality- adjusted life years ($/QALY). Our results showed that the no treatment strategy was associated with a cost of $38,747 and 13.10 QALYs. The strategy using IFN alone for 48 weeks was associated with a cost of $35,642 and 14.05 QALYs. The strategy using IFN monotherapy followed by combination therapy for nonresponders and relapsers was associated with a cost of $34,561 and 15.53 QALYs. A similar strategy, but limiting combination to relapsers only, was associated with a cost of $34,758 and 14.40 QALYs. The strategy using IFN with ribavirin as the initial therapy for all patients was associated with a cost of $34,792 and 15.31 QALYs. Finally, the strategy using viral genotyping first and then adjusting the duration of combination therapy based on genotype was associated with a cost of $37,263 and 15.89 QALYs. The strategy using genotyping to guide duration of combination therapy was the most cost- effective approach with an incremental cost-effectiveness ratio of $7,500 per QALY. Sensitivity analyses confirmed the robustness of these results. We conclude that combination of IFN and ribavirin with duration of therapy based on the viral genotype, is a cost-effective approach in treating patients with chronic hepatitis C.

UR - http://www.scopus.com/inward/record.url?scp=0032731788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032731788&partnerID=8YFLogxK

U2 - 10.1002/hep.510300518

DO - 10.1002/hep.510300518

M3 - Article

C2 - 10534357

AN - SCOPUS:0032731788

VL - 30

SP - 1318

EP - 1324

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 5

ER -